Benefits of combining the sexes when evaluating data from toxicological studies

Area of Science:

• Pharmacology
• Toxicology
• Biostatistics

Background:

• Drug safety assessment relies heavily on toxicological studies.
• Current practice often involves analyzing data from males and females separately.
• This separation may lead to inefficiencies and suboptimal data interpretation.

Purpose of the Study:

• To advocate for the combined analysis of toxicological data from both sexes.
• To highlight the benefits of integrated sex data in drug safety evaluations.
• To demonstrate how combined analysis can enhance efficiency and reduce animal usage.

Main Methods:

• Reviewing established practices in toxicological data analysis.
• Presenting arguments for combining sex data, including efficiency, clinical trial parallels, and improved statistical power.
• Illustrating the proposed methodology with real study data and theoretical quantification.
• Recommending statistical approaches that account for sex differences within combined analyses.

Main Results:

• Combining sex data offers improved efficiency, potentially reducing the number of animals needed by up to 50% without compromising precision.
• Integrated analysis facilitates the quantification of sex differences when they exist.
• The approach leads to a reduction in false positive and false negative findings.
• Real-world data demonstrated substantial benefits over traditional separate-sex analyses.

Conclusions:

• Combining toxicological data from both sexes is a superior practice for drug safety assessment.
• This integrated approach enhances efficiency, reduces animal use, and improves the reliability of findings.
• Statistical methods allowing for sex as a factor are crucial for effective combined analysis.